How does bicalutamide work in the body?
Bicalutamide is a nonsteroidal antiandrogen. It blocks the action of androgens (mainly testosterone and its more potent metabolite, dihydrotestosterone) at the androgen receptor. By preventing androgen receptor signaling, it reduces androgen-driven growth and survival of androgen-dependent cells, which is most relevant in prostate cancer. [1]
What does it bind to—does it lower testosterone?
Bicalutamide acts as an androgen receptor antagonist (it prevents the receptor from being activated by androgens). It does not directly inhibit testosterone production. In prostate cancer treatment, it is commonly used alongside therapies that lower testicular androgen production (e.g., LHRH analogs) to more completely reduce androgen effects. [1]
Why does it take effect slowly?
Because its primary action is blocking receptor signaling rather than immediately lowering hormone levels, the clinical effect reflects the downstream reduction of androgen-driven gene expression over time. This is why bicalutamide is used as part of androgen-deprivation strategies rather than as a rapid “hormone shutdown.” [1]
What are the main consequences of androgen-receptor blockade?
When androgen receptor signaling is blocked, androgen-dependent processes (including tumor cell growth and survival programs controlled by androgen-responsive genes) are suppressed. This underlies its use in prostate cancer where tumor activity depends on androgen signaling. [1]
Does bicalutamide have any agonist activity?
As an antiandrogen, bicalutamide’s intended pharmacologic role is antagonism at the androgen receptor. In some contexts (for example, with changes in receptor expression or tumor adaptations), antiandrogens can have altered effects, which is one reason cancers can eventually progress even on therapy. The core mechanism remains androgen receptor blockade. [1]
---
Sources
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016786